Sun Pharma of India and Mylan Pharmaceuticals of West Virginia seek FDA approval of generic versions of the popular ...

While Novo is struggling to keep up with demand for its obesity drugs, U.S. rival Eli Lilly sees supply restraints easing.

A woman who used the semaglutide drugs Wegovy and Ozempic to lose weight and treat diabetes says the drugmaker didn't ...

Novo Nordisk 's ( NVO 1.19%) GLP-1 medicines, Ozempic and Wegovy, are bestsellers and household names. Whereas Ozempic is ...

Novo Nordisk’s Wegovy cut the risk of severe complications in patients with a common form of heart failure, according to a ...

Today, patients on insulin receive injections daily, or even more often, but both companies are working to change that.

Novo Nordisk's launch of weight-loss and diabetes drugs Wegovy and Ozempic in India hinges on resolving supply issues. The ...

We recently compiled a list of the 12 Best Biotech Stocks To Invest In According To Hedge Funds. In this article, we are ...

Novo Nordisk's (NVO) weight loss drug Wegovy (semaglutide), which can be prescribed to Medicare beneficiaries who are both obese and have cardiovascular disease, could cost the system up to $145B ...

Looking for successors to the blockbuster GLP-1 obesity drugs, companies like Novo Nordisk and Eli Lilly are testing amylin ...

Also Read: Novo Nordisk Does Not Operate As Drug Cartel, CEO Defends US Pricing Of Ozempic Against Criticism Over High Drug ...

Novo Nordisk is working to resolve supply issues that are affecting the launch of its weight-loss and diabetes medications, ...